Condition: Valve Disease, Heart · Valve Replacement · Valve Regurgitation, Mitral · Sponsor: Michael Moront
The safety and efficacy of the Mosaic bioprosthetic heart valves for cardiac valve replacement in the aortic position has been well documented throughout the literature. However, few studies assessing structural valve deficiency, patient outcomes and overall product performance in patients under the age of 65 exists for the Mosaic mitral valve bioprosthetic. This study aims to assess valve efficacy, stability, and post operative outcomes in patients who have received the Mosaic mitral valve prothesis at ProMedica Toledo Hospital and were under the age of 65.
This description comes directly from the study's public registry record.
Dawn Muskiewicz, MS · 419-291-7517 · dawn.muskiewicz@promedica.org
Leah Stevenson, MS · 419-291-3419 · leah.stevenson@promedica.org
Always discuss trial participation with your own doctor first.
| ProMedica Toledo Hospital | Toledo, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06917586